Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00552344 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase 3 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 403
- Enrollment target
NCT00552344 is a Phase 3 study that has completed, run by UCB Biosciences. The registered enrollment target is 403 participants.
The verdict
NCT00552344, a Phase 3 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 403 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the safety of long term therapy with Certolizumab Pegol in those subjects participating in study C87085 \[NCT00552058\].
Interventions
- BIOLOGICAL Cimzia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2008-05 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00552344
The ClinicalTrials.gov registry entry for NCT00552344 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 403 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cimzia is the first listed.
NCT00552344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00552344 about?
NCT00552344 is a clinical study titled "A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease". The primary objective of the study is to assess the safety of long term therapy with Certolizumab Pegol in those subjects participating in study C87085 \[NCT00552058\].
What is the current status of trial NCT00552344?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 403 participants. The study started on 2008-05. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00552344?
The interventions under investigation include: Cimzia (BIOLOGICAL).
Who is sponsoring clinical trial NCT00552344?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.